niacin

Summary

Summary: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

Top Publications

  1. pmc Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis
    Nagendra Singh
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA Electronic address
    Immunity 40:128-39. 2014
  2. pmc Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms
    Janet E Digby
    Department of Cardiovascular Medicine, John Radcliffe Hospital, and Sir William Dunn School of Pathology, University of Oxford, Oxford, OX3 9DU, UK
    Arterioscler Thromb Vasc Biol 32:669-76. 2012
  3. pmc Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
  4. doi Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA 90822, United States
    Atherosclerosis 202:68-75. 2009
  5. pmc Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
    Gregory C Shearer
    Sanford Research USD, University of South Dakota, Sioux Falls, SD, USA
    J Lipid Res 53:2429-35. 2012
  6. pmc Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 121:1163-73. 2011
  7. ncbi PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
    Sorin Tunaru
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Nat Med 9:352-5. 2003
  8. doi The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
    Todd C Villines
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Am Coll Cardiol 55:2721-6. 2010
  9. doi Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    Eric Bruckert
    Department of Endocrinology, Pitie Salpetriere University Hospital, Pierre and Marie Curie University, 83 bd de l hopital, 75651, Paris, France
    Atherosclerosis 210:353-61. 2010
  10. ncbi Niacin and cholesterol: role in cardiovascular disease (review)
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California, USA
    J Nutr Biochem 14:298-305. 2003

Detail Information

Publications337 found, 100 shown here

  1. pmc Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis
    Nagendra Singh
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA Cancer Research Center, Georgia Regents University, Augusta, GA 30912, USA Electronic address
    Immunity 40:128-39. 2014
    ..GPR109A (encoded by Niacr1) is a receptor for butyrate in the colon. GPR109A is also a receptor for niacin, which is also produced by gut microbiota and suppresses intestinal inflammation...
  2. pmc Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms
    Janet E Digby
    Department of Cardiovascular Medicine, John Radcliffe Hospital, and Sir William Dunn School of Pathology, University of Oxford, Oxford, OX3 9DU, UK
    Arterioscler Thromb Vasc Biol 32:669-76. 2012
    ..We hypothesize that NA has the potential to act directly on monocytes to alter mediators of inflammation that may contribute to its antiatherogenic effects in vivo...
  3. pmc Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
    ..e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly ..
  4. doi Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA 90822, United States
    Atherosclerosis 202:68-75. 2009
    In pharmacological doses, nicotinic acid (niacin) reduces myocardial infarction, stroke and atherosclerosis. The beneficial effects of niacin on lipoproteins are thought to mediate these effects...
  5. pmc Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
    Gregory C Shearer
    Sanford Research USD, University of South Dakota, Sioux Falls, SD, USA
    J Lipid Res 53:2429-35. 2012
    The metabolic syndrome includes both dyslipidemia and impaired vascular function. Because extended-release niacin (ERN) and prescription omega-3 acid ethyl-esters (P-OM3) independently improve these characteristics, we tested their ..
  6. pmc Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 121:1163-73. 2011
    Nicotinic acid (niacin) is a drug used to reduce the progression of atherosclerosis...
  7. ncbi PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
    Sorin Tunaru
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Nat Med 9:352-5. 2003
    Nicotinic acid (niacin), a vitamin of the B complex, has been used for almost 50 years as a lipid-lowering drug. The pharmacological effect of nicotinic acid requires doses that are much higher than those provided by a normal diet...
  8. doi The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
    Todd C Villines
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Am Coll Cardiol 55:2721-6. 2010
    ..This report describes the final results of the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial...
  9. doi Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    Eric Bruckert
    Department of Endocrinology, Pitie Salpetriere University Hospital, Pierre and Marie Curie University, 83 bd de l hopital, 75651, Paris, France
    Atherosclerosis 210:353-61. 2010
    ....
  10. ncbi Niacin and cholesterol: role in cardiovascular disease (review)
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California, USA
    J Nutr Biochem 14:298-305. 2003
    b>Niacin has been widely used as a pharmacologic agent to regulate abnormalities in plasma lipid and lipoprotein metabolism and in the treatment of atherosclerotic cardiovascular disease...
  11. ncbi The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target
    Stefan Offermanns
    Institute of Pharmacology, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany
    Trends Pharmacol Sci 27:384-90. 2006
    ....
  12. ncbi Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    N Engl J Med 345:1583-92. 2001
    ..We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary ..
  13. pmc GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon
    Muthusamy Thangaraju
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, USA
    Cancer Res 69:2826-32. 2009
    ..These studies show that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon...
  14. doi GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy
    Deeksha Gambhir
    Department of Biochemistry and Molecular Biology, and the Vision Science Discovery Institute, Georgia Health Sciences University, Augusta, Georgia 30912, USA
    Invest Ophthalmol Vis Sci 53:2208-17. 2012
    Retinal pigment epithelium (RPE) expresses GPR109A, a receptor for the vitamin niacin and the ketone body β-hydroxybutyrate (β-HB)...
  15. pmc Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment
    Sangdun Choi
    Department of Molecular Science and Technology, Ajou University, Suwon, South Korea
    Metabolism 60:134-44. 2011
    Nicotinic acid (NA; or niacin) has been used as a hypolipidemic agent for more than 4 decades. However, the mechanisms underlying the effects of NA treatment (wanted and unwanted) are still poorly understood...
  16. doi Niacin: the evidence, clinical use, and future directions
    Todd C Villines
    Cardiology Service, Department of Medicine, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA
    Curr Atheroscler Rep 14:49-59. 2012
    The use of FDA-approved niacin (nicotinic acid or vitamin B3) formulations at therapeutic doses, alone or in combination with statins or other lipid therapies, is safe, improves multiple lipid parameters, and reduces atherosclerosis ..
  17. ncbi Niacin status, NAD distribution and ADP-ribose metabolism
    James B Kirkland
    Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1
    Curr Pharm Des 15:3-11. 2009
    Dietary niacin deficiency, and pharmacological excesses of nicotinic acid or nicotinamide, have dramatic effects on cellular NAD pools, ADP-ribose metabolism, tissue function and health...
  18. ncbi Niaspan increases angiogenesis and improves functional recovery after stroke
    Jieli Chen
    Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Ann Neurol 62:49-58. 2007
    High-density lipoprotein (HDL) is implicated in the modulation of angiogenesis. In this study, we investigated whether the Niacin-mediated increase of HDL regulates angiogenesis and thereby improves functional outcome after stroke.
  19. ncbi Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Biochem Pharmacol 71:646-56. 2006
    HM74 and HM74a have been identified as receptors for niacin. HM74a mediates the pharmacological anti-lipolytic effects of niacin in adipocytes by reducing intracellular cyclic AMP (cAMP) and inhibiting release of free fatty acids into the ..
  20. ncbi Why do some yeast species require niacin for growth? Different modes of NAD synthesis
    You Fang Li
    CNRS UMR 8621, Institut de Genetique et Microbiologie, Universite Paris Sud 11, Orsay, France
    FEMS Yeast Res 7:657-64. 2007
    ..lactis. The results suggested that the basis of the variation of niacin requirements in yeasts lies in their different combinations of NAD biosynthesis pathways...
  21. ncbi Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes
    M J Watt
    Skeletal Muscle Research Laboratory, School of Medical Sciences, Royal Melbourne Institute of Technology, PO Box 27, Bundoora 3083, Victoria, Australia
    J Mol Endocrinol 33:533-44. 2004
    ..Despite these changes in transcription factors/coactivators, the mRNA content of lipid regulatory proteins was generally unaffected by plasma FFA availability...
  22. pmc Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom
    Atherosclerosis 209:89-95. 2010
    ....
  23. ncbi Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 334:729-32. 2005
    A G-protein coupled receptor to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined...
  24. doi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
    ....
  25. pmc Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice
    Julien Hanson
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 120:2910-9. 2010
    ..These data will help to guide new efficient approaches to mitigate nicotinic acid-induced flushing and may help to exploit the potential antipsoriatic effects of GPR109A agonists in the skin...
  26. pmc Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:1430-8. 2010
    To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated ..
  27. ncbi Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits
    Shui Ping Zhao
    Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
    Int J Cardiol 124:172-8. 2008
    ..The aim of this study was to evaluate the effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes from hypercholesterolemic ..
  28. pmc beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice
    Robert W Walters
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 119:1312-21. 2009
    ..Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia...
  29. doi Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury
    Suresh Varma Penumathsa
    Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1110, USA
    Biochim Biophys Acta 1792:39-48. 2009
    ..We investigated the effect of niacin-bound chromium (NBC) during ischemia/reperfusion (IR) injury in streptozotocin induced diabetic rats...
  30. doi Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids
    Ben J Wu
    Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, New South Wales, Australia 2042
    Arterioscler Thromb Vasc Biol 30:968-75. 2010
    To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels.
  31. ncbi Molecular identification of high and low affinity receptors for nicotinic acid
    Alan Wise
    Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Biol Chem 278:9869-74. 2003
    ..The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia...
  32. doi Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes
    Zhi hong Wu
    Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan 410011, PR China
    Pharmacology 84:282-7. 2009
    The mechanism by which niacin increases plasma levels of high-density lipoprotein cholesterol (HDL-C) is not clearly understood yet...
  33. doi What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
    Harold E Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Curr Opin Lipidol 20:467-76. 2009
    b>Niacin is a B-complex vitamin used as a lipid-altering drug since the 1950s. Niacin improves multiple lipid parameters...
  34. ncbi Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
    J M McKenney
    School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
    Am J Cardiol 88:270-4. 2001
    This study was conducted to determine the efficacy of atorvastatin and niacin on lipoprotein subfractions in patients with atherogenic dyslipidemia...
  35. doi Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou
    Erin D Michos
    The Johns Hopkins University School of Medicine, Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland 21287, USA
    J Am Coll Cardiol 59:2058-64. 2012
    ..Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with ..
  36. pmc Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois College of Medicine, Peoria, CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA
    Vasc Health Risk Manag 8:39-44. 2012
    The purpose of this research was to compare the effects of niacin extended-release in combination with simvastatin (NER/S) versus atorvastatin monotherapy on high-density lipoprotein (HDL) particle number and size in patients with ..
  37. pmc Intravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humans
    Robert H Nelson
    Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA
    Diabetes 61:3172-5. 2012
    ..overweight and obese (n = 5) subjects during continuous feeding on two occasions: during intravenous infusion of niacin (2.8 mg/min) and saline...
  38. ncbi Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 18:415-20. 2007
    This review describes niacin's mechanism of action, efficacy in cardiovascular prevention, and safety.
  39. pmc Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice
    Desiree Wanders
    Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
    PLoS ONE 8:e71285. 2013
    To determine the effects of niacin on adiponectin and markers of adipose tissue inflammation in a mouse model of obesity.
  40. doi Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice
    Zhaosha Li
    Division of Biopharmaceutics, Leiden Amsterdam Center for Drug Research, Leiden University, The Netherlands
    Biochem Pharmacol 84:821-9. 2012
    The anti-dyslipidemic drug niacin has recently been shown to reduce the hepatic expression and plasma levels of CETP...
  41. ncbi Change in alpha1 HDL concentration predicts progression in coronary artery stenosis
    Bela F Asztalos
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Center on Aging at Tufts University and Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine, New England Medical Center, Boston, Mass 02111, USA
    Arterioscler Thromb Vasc Biol 23:847-52. 2003
    We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography.
  42. doi Niacin inhibits vascular inflammation via the induction of heme oxygenase-1
    Ben J Wu
    Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, NSW, Australia, 2042
    Circulation 125:150-8. 2012
    ..b>Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 ..
  43. doi The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression
    Paul M Lavigne
    Molecular Cardiology Research Institute, Division of Cardiology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 61:440-6. 2013
    This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis ..
  44. pmc Niaspan increases axonal remodeling after stroke in type 1 diabetes rats
    Tao Yan
    Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China
    Neurobiol Dis 46:157-64. 2012
    ..We investigated axonal plasticity in the bilateral motor cortices and the long term therapeutic effect of Niaspan on axonal remodeling after stroke in type-1 diabetic (T1DM) rats...
  45. doi Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
    Vummidi Giridhar Premkumar
    Department of Medical Biochemistry, DR A L M Post Graduate, Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, Tamil Nadu, India
    Br J Nutr 100:1179-82. 2008
    ..cancer patients were randomized to receive a daily supplement of 100 mg co-enzyme Q10, 10 mg riboflavin and 50 mg niacin (CoRN), one dosage per d along with 10 mg tamoxifen twice per d...
  46. doi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
    ..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL.
  47. doi Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study
    Vasu Babu Ravi
    Research Studies, Rayalaseema University, Kurnool 518 002, India
    Biomed Chromatogr 26:1436-43. 2012
    ..and selective LC-MS/MS method has been developed and validated for quantification of the atorvastatin (AT) and niacin (NA) in 250 μL human plasma...
  48. ncbi Adipokines and treatment with niacin
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, D 39120 Magdeburg, Germany
    Metabolism 55:1283-5. 2006
    ..Because adipose tissue is one site of action of the lipid-lowering drug niacin, we investigated whether niacin treatment would affect not only lipids but also adipokines...
  49. pmc Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells
    Lin Hua Zhang
    Atherosclerosis Research Center, Veterans Affairs Healthcare System, Long Beach, CA, USA
    J Lipid Res 53:941-50. 2012
    ..b>Niacin is the most effective lipid-regulating agent clinically available to raise HDL...
  50. ncbi Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
    M C Cheung
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, School of Medicine, University of Washington, Seattle 98103, USA
    Arterioscler Thromb Vasc Biol 21:1320-6. 2001
    ..low HDL cholesterol (HDL-C) is to maximally increase the HDL-C to LDL-C ratio by combining lifestyle changes with niacin (N) plus a statin...
  51. ncbi Langerhans cells release prostaglandin D2 in response to nicotinic acid
    Dominique Maciejewski-Lenoir
    Arena Pharmaceuticals Inc, San Diego, California 92121, USA
    J Invest Dermatol 126:2637-46. 2006
    ..These results suggest that nicotinic acid mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of PGD(2)...
  52. doi Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease
    Jasleen K Duggal
    Chicago Medical School and Affiliated Hospitals, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
    J Cardiovasc Pharmacol Ther 15:158-66. 2010
    b>Niacin or nicotinic acid (vitamin B3) raises the levels of high-density lipoprotein cholesterol (HDL) by about 30% to 35%...
  53. ncbi Safety and toxicological evaluation of a novel niacin-bound chromium (III) complex
    Michael Shara
    Creighton University Medical Center, Omaha, NE, USA
    J Inorg Biochem 99:2161-83. 2005
    ..It also helps in energy production and increasing lean body mass. Niacin-bound chromium (NBC) is a unique form of bioavailable chromium that promotes healthy lipid profile...
  54. doi Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    S Shah
    Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Int J Clin Pract 64:727-38. 2010
    Co-administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction...
  55. pmc Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Building 2, Room 4A34, Washington, DC 20307 5001, USA
    Vasc Health Risk Manag 3:159-64. 2007
    We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy...
  56. ncbi Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush
    C Daniel Meyers
    Long Beach Veterans Affairs Healthcare System, Long Beach, CA, United States
    Atherosclerosis 192:253-8. 2007
    ..shown to prevent cardiovascular disease, yet its widespread use is limited by the prostaglandin D2 (PGD2) mediated niacin flush...
  57. pmc Niacin treatment of stroke increases synaptic plasticity and axon growth in rats
    Xu Cui
    Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
    Stroke 41:2044-9. 2010
    b>Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein cholesterol...
  58. ncbi Extended-release niacin raises adiponectin and leptin
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, Leipziger Str 44, D 39120 Magdeburg, Germany
    Atherosclerosis 193:361-5. 2007
    The lipid-lowering drug niacin has attracted renewed interest because it raises HDL-cholesterol and because it has recently been found to slow down the progression of intima media thickness in patients with coronary heart disease...
  59. pmc High-affinity transporters for NAD+ precursors in Candida glabrata are regulated by Hst1 and induced in response to niacin limitation
    Biao Ma
    Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 2185, USA
    Mol Cell Biol 29:4067-79. 2009
    ..C. glabrata is a NAD(+) auxotroph, and its growth depends on the availability of niacin (environmental vitamin precursors of NAD(+))...
  60. doi Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure
    Kyu hyang Cho
    Division of Nephrology and Hypertension, University of California, Irvine, California, USA
    Am J Physiol Renal Physiol 297:F106-13. 2009
    ..b>Niacin is known to improve lipid metabolism and exert antioxidant/anti-inflammatory actions...
  61. ncbi Aerobic and anaerobic NAD+ metabolism in Saccharomyces cerevisiae
    Cristina Panozzo
    Centre de Genetique Moleculaire, Laboratoire propre du CNRS, associé à l Université Pierre et Marie Curie, Gif sur Yvette, France
    FEBS Lett 517:97-102. 2002
    ..cerevisiae. Also, we show that under anaerobic conditions S. cerevisiae is a nicotinic acid auxotroph...
  62. ncbi The nicotinic acid receptor--a new mechanism for an old drug
    Fredrik Karpe
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Lancet 363:1892-4. 2004
    ..Suppression of lipolysis by nicotinic acid gives rise to a prominent rebound and the degree to which this occurs might explain this paradox...
  63. doi Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
    M John Chapman
    Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie Salpetriere, Paris, France
    Pharmacol Ther 126:314-45. 2010
    ..In this context, there is renewed interest in pharmacotherapeutic strategies involving niacin and fibrates in monotherapy and in association with statins...
  64. ncbi Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA, USA
    J Lipid Res 45:1835-45. 2004
    b>Niacin is a widely used lipid-regulating agent in dyslipidemic patients. Previously, we have shown that niacin inhibits triacylglycerol synthesis...
  65. pmc Combined statin and niacin therapy remodels the high-density lipoprotein proteome
    Pattie S Green
    Department of Medicine, University of Washington, Seattle, WA, USA
    Circulation 118:1259-67. 2008
    ..We hypothesized that an intervention that increases HDL levels-combined statin and niacin therapy-might reverse these changes.
  66. doi Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
    Justin M S Lee
    Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
    J Am Coll Cardiol 54:1787-94. 2009
    ..Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function...
  67. ncbi Nicotinic acid: pharmacological effects and mechanisms of action
    Andreas Gille
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Annu Rev Pharmacol Toxicol 48:79-106. 2008
    ....
  68. ncbi Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss
    H G Preuss
    Department of Physiology and Biophysics, Georgetown University Medical Center, Georgetown, Washington, DC 20057, USA
    Diabetes Obes Metab 6:171-80. 2004
    The efficacy of optimal doses of highly bioavailable (-)-hydroxycitric acid (HCA-SX) alone and in combination with niacin-bound chromium (NBC) and a standardized Gymnema sylvestre extract (GSE) on weight loss in moderately obese subjects ..
  69. pmc Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes
    Claudia A Benavente
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Free Radic Biol Med 44:527-37. 2008
    ..Removal of niacin from the cell culture medium allowed control of intracellular NAD...
  70. doi Nicotinic acid and the prevention of coronary artery disease
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, UK
    Curr Opin Lipidol 20:321-6. 2009
    ..at all levels of LDL cholesterol has, therefore, given renewed emphasis on the therapeutic potential of niacin. The purpose of this review is to evaluate advances in the elucidation of mechanisms by which nicotinic acid ..
  71. pmc Chronic niacin overload may be involved in the increased prevalence of obesity in US children
    Da Li
    Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, Liaoning Province, China
    World J Gastroenterol 16:2378-87. 2010
    To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence.
  72. doi Niacin stimulates adiponectin secretion through the GPR109A receptor
    Eric P Plaisance
    Department of Anatomy, Auburn University, Auburn, AL 36849, USA
    Am J Physiol Endocrinol Metab 296:E549-58. 2009
    b>Niacin (nicotinic acid) has recently been shown to increase serum adiponectin concentrations in men with the metabolic syndrome...
  73. doi Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
    b>Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing.
  74. doi Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model
    Dean Papaliodis
    Department of Pharmacology and Experimental Therapeutics, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    J Pharmacol Exp Ther 327:665-72. 2008
    b>Niacin lowers serum cholesterol, low-density lipoprotein, and triglycerides, and it raises high-density lipoprotein. However, most patients experience cutaneous warmth and vasodilation (flush)...
  75. ncbi A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin
    Elaine L Jacobson
    Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ 85724, USA
    Exp Dermatol 16:490-9. 2007
    ....
  76. ncbi Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects
    Crystal A Gadegbeku
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
    Am J Hypertens 16:67-71. 2003
    ..The adjustment in vascular compliance may be an important factor in determining overall BP response to NA...
  77. ncbi Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients
    Daniela Muller
    Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charite, HELIOS Klinikum Berlin, Berlin, Germany
    Clin J Am Soc Nephrol 2:1249-54. 2007
    ..Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed...
  78. doi Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview
    Ramesh Mullangi
    Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd, Industrial Suburb, Yeshwanthpur, Bangalore 560 022, India
    Biomed Chromatogr 25:218-37. 2011
    b>Niacin (nicotinic acid), although an old drug, has seen a sudden surge in popularity for treatment of lipid disorders and other associated clinical conditions for the prevention of cardiovascular risk...
  79. pmc High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice
    Alan M Kwong
    Division of Medical Genetics, Department of Pediatrics, Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Nutr Cancer 63:950-9. 2011
    High doses of niacin (nicotinic acid) used to treat dyslipidemias cause flushing, due to high levels of prostaglandin D(2) (PGD(2)). GPR109A, a G-protein coupled receptor, triggers the flushing in the skin...
  80. doi Niacin-bound chromium increases life span in Zucker Fatty Rats
    Harry G Preuss
    Georgetown University Medical Center, Department of Biochemistry Physiology, Washington, D C 20057, United States
    J Inorg Biochem 105:1344-9. 2011
    ..We assessed whether consuming niacin-bound chromium (NBC) alone or in a formula containing other so-called "insulin sensitizers" would overcome various ..
  81. doi Increased total and high-molecular weight adiponectin after extended-release niacin
    Eric P Plaisance
    Department of Anatomy, Physiology and Pharmacology, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL 36849, USA
    Metabolism 57:404-9. 2008
    b>Niacin has recently been shown to increase serum total concentrations of the adipocyte-derived protein adiponectin...
  82. ncbi Zinc, metallothioneins and longevity: interrelationships with niacin and selenium
    E Mocchegiani
    Immunology Center, Laboratory of Nutrigenomic and Immunosenescence, Research Department INRCA, Via Birarelli, 8, 60121, Ancona, Italy
    Curr Pharm Des 14:2719-32. 2008
    ..Some nutritional factors (zinc, niacin, selenium) may remodel these changes leading to a possible escaping of diseases, with the consequence of healthy ..
  83. pmc The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
    Edward Mills
    Department of Research, Canadian College of Naturopathic Medicine, North York, Canada
    BMC Clin Pharmacol 3:4. 2003
    b>Niacin is widely available over the counter (OTC). We sought to determine the safety of 500 mg immediate release niacin, when healthy individuals use them as directed.
  84. pmc A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention
    Terry A Jacobson
    Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University, Faculty Office Building, 49 Jessie Hill Jr Dr SE, Atlanta, GA 30303, USA
    Mayo Clin Proc 85:365-79. 2010
    b>Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing...
  85. ncbi Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine
    H J Powers
    Division of Child Health, University of Sheffield, Sheffield Children s Hospital, UK
    Proc Nutr Soc 58:435-40. 1999
    ..The present short review considers the current position regarding such markers for riboflavin, pyridoxine and niacin. It is concluded that whilst there are several biochemical measures which respond to changes in intake of each of ..
  86. pmc Niacin protects against UVB radiation-induced apoptosis in cultured human skin keratinocytes
    Fuquan Lin
    Department of Dermatology, Third People s Hospital of Hangzhou, Hangzhou 310009, PR China
    Int J Mol Med 29:593-600. 2012
    b>Niacin and its related derivatives have been shown to have effects on cellular activities. However, the molecular mechanism of its reduced immunosuppressive effects and photoprotective effects remains unclear...
  87. ncbi Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice
    R S Birjmohun
    Department of Vascular Medicine, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands
    Neth J Med 62:229-34. 2004
    ..The inverse relation between high-density lipoprotein cholesterol (HDL-C) and cardiovascular (CV) disease underscores the need for clinical evaluation of the effect of HDL-C increasing drugs on the prevalence of CV disease...
  88. ncbi Sustained-release niacin for prevention of migraine headache
    David A Velling
    Division of Pain Management Mayo Clinic, Scottsdale, Ariz 85259, USA
    Mayo Clin Proc 78:770-1. 2003
    ..We describe a patient whose migraine headaches responded dramatically to sustained-release niacin as preventive treatment. Niacin is not generally considered to be effective for migraine prevention...
  89. doi Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles
    Srinivasan Yuvaraj
    Department of Medical Biochemistry, Dr ALMP GIBMS, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India
    Breast Cancer Res Treat 114:377-84. 2009
    ..Coenzyme Q(10), Riboflavin and Niacin (CoRN) are well-known potent antioxidants and protective agents against many diseases including cancer...
  90. ncbi The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
    M Thoenes
    Institut fur Klinische Pharmakologie, Technische Universitat Dresden, Dresden, Germany
    Int J Clin Pract 61:1942-8. 2007
    b>Niacin is an agent that significantly increases high-density lipoprotein cholesterol (HDL-C), but its effects on surrogate markers of atherosclerosis and inflammatory markers are less clear...
  91. ncbi Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash--a case report
    Joseph Martin Alisky
    Marshfield Clinic Research Foundation, 1000 Oak Avenue, Marshfield, WI 54449, USA
    Nutr Neurosci 8:327-9. 2005
    A patient with Parkinson's disease taking levodopa/carbidopa, selegiline, buproprion, aspirin and niacin had decreased rigidity and bradykinesia when his niacin dose was steadily escalated for treatment of high triglycerides, but ..
  92. pmc Effects of niacin restriction on sirtuin and PARP responses to photodamage in human skin
    Claudia A Benavente
    Arizona Cancer Center and Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, United States of America
    PLoS ONE 7:e42276. 2012
    ..b>Niacin restriction, which decreases NAD(+), the sirtuin substrate, results in an increase in acetylated proteins, ..
  93. doi High-density lipoprotein particles, coronary heart disease, and niacin
    Bela F Asztalos
    Lipid Metabolism Laboratory, Tufts University, 711 Washington Street, Boston, MA 02111, USA
    J Clin Lipidol 4:405-10. 2010
    ..Based on the Framingham Heart Study data, HDL-C <35 mg/dl was established an independent risk factor and HDL-C >60 mg/dl as protective.(3) Presently the cut point is <40 mg/dl for men and <50 mg/dl for women...
  94. doi Niacin requirements for genomic stability
    James B Kirkland
    Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1
    Mutat Res 733:14-20. 2012
    Through its involvement in over 400 NAD(P)-dependent reactions, niacin status has the potential to influence every area of metabolism...
  95. ncbi Low and deficient niacin status and pellagra are endemic in postwar Angola
    Andrew J Seal
    Centre for International Child Health, Institute of Child Health, London, United Kingdom
    Am J Clin Nutr 85:218-24. 2007
    Outbreaks of pellagra were documented during the civil war in Angola, but no contemporary data on the incidence of pellagra or the prevalence of niacin deficiency were available.
  96. pmc Niacin supplementation induces type II to type I muscle fiber transition in skeletal muscle of sheep
    Muckta Khan
    Institute of Animal Nutrition and Nutrition Physiology, Justus Liebig University Giessen, Heinrich Buff Ring 26 32, 35390 Giessen, Germany
    Acta Vet Scand 55:85. 2013
    It was recently shown that niacin supplementation counteracts the obesity-induced muscle fiber transition from oxidative type I to glycolytic type II and increases the number of type I fibers in skeletal muscle of obese Zucker rats...
  97. ncbi Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance
    Annette M Chang
    5570 MSRB II, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109 0678, USA
    J Clin Endocrinol Metab 91:3303-9. 2006
    ..Glucose tolerance declines with age and may involve impaired beta-cell sensitivity to glucose and beta-cell compensation for insulin resistance...
  98. doi Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study
    Eric J Niesor
    Pharma Research and Early Development, Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Bldg 70 411 Grenzacherstrasse 124, 4070, Basel, Switzerland
    Lipids 48:1185-96. 2013
    Fenofibrate and extended-release (ER) niacin similarly raise high-density lipoprotein cholesterol (HDL-C) concentration but their effects on levels of potent plasma antioxidant xanthophylls (lutein and zeaxanthin) and phytosterols ..
  99. doi Recent advances in niacin and lipid metabolism
    Vaijinath S Kamanna
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California 90822, USA
    Curr Opin Lipidol 24:239-45. 2013
    This review focuses on the current understanding of the physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis.
  100. doi Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany
    Trends Pharmacol Sci 32:700-7. 2011
    Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis...

Research Grants63

  1. Novel mechanisms of niacin to improve HDL function: Role of myeloperoxidase
    Moti L Kashyap; Fiscal Year: 2013
    ..Nicotinic acid (Niacin) is a widely used agent in the treatment of dyslipidemia, and clinical trials indicate that the treatment with ..
  2. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher P Duggan; Fiscal Year: 2010
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  3. A Novel Approach to Phosphorus Lowering in Patients with Chronic Kidney Disease
    Joachim H Ix; Fiscal Year: 2013
    ..The lipid drug niacin contains both nicotinamide and nicotinic acid, and we have shown that it lowers Pi in CKD patients...
  4. CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
    George Timothy Bowden; Fiscal Year: 2013
    ..abstract_text> ..
  5. FFA Production From Triglyceride-Rich Lipoproteins
    John M Miles; Fiscal Year: 2013
    ..Subsequent studies have shown that intravenous infusion of niacin, a drug known to suppress FFA release, produced a significant reduction in fractional spillover, whereas insulin ..
  6. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
    Emmanouil Brilakis; Fiscal Year: 2013
    ..b>Niacin raises HDL-C, restores the re-endothelialization capacity of EPCs, and slowed the progression of SVG ..
  7. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie G Brouillette; Fiscal Year: 2010
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  8. ENZYMATIC REACTIONS OF PLASMA LIPOPROTEINS
    Henry J Pownall; Fiscal Year: 2010
    ..Although niacin and the statin class of hypolipidemic drugs can increase HDL-C, their effects are modest and better HDL therapies ..
  9. Niacin-mediated migration of monocyte-derived cells in atherosclerosis
    MOLLY INGERSOLL; Fiscal Year: 2010
    ..protocol to trace migration of monocyte subsets in mouse atherosclerotic plaques, demonstrated that intake of 1% niacin supplemented diet promoted monocyte-derived cell egress from plaques rescuing monocytes from dying in necrotic ..
  10. Mechanism of HPA Axis Activation: Role of Nicotinic Acid Receptor in the Brain
    Jang H Youn; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Nicotinic acid (NA;or niacin) is a water-soluble vitamin...
  11. Niacin therapy to improve endothelial function in Sickle Cell Disease
    NAOMI L LUBAN; Fiscal Year: 2011
    ..We propose a forearm blood flow physiology study with Niaspan, a slow release form of niacin, previously reported to increase high density lipoprotein (HDL) and apo A-l levels...
  12. Phospholipid-Arachidonate-Eicosanoid Signaling in Schizophrenia
    Jeffrey K Yao; Fiscal Year: 2013
    ..Further, we propose that phospholipid-arachidonate-eicosanoid (PAE) signaling abnormalities are responsible for niacin subsensitivity (the reduced sensitivity to the skin flush effect of niacin), which is among the most widely-..
  13. AIM-HIGH
    RUTH M MCBRIDE; Fiscal Year: 2010
    ..controlled clinical trial designed to test the hypothesis that the drug combination of extended-release (ER-) niacin plus simvastatin is superior to simvastatin alone, at comparable levels of intreatment LDL-cholesterol, for ..
  14. Niacin's effect on fatty acids and inflammatory markers (NEFA-IM)
    RICHARD LOUIS DUNBAR; Fiscal Year: 2012
    ..Specific hypotheses related to Niacin's Effects on Fatty Acids and Inflammatory Markers (NEFA-IM) are assessed using a niacin challenge to provoke ..
  15. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
    JEFFREY LYNN PROBSTFIELD; Fiscal Year: 2010
    AIM-HIGH is a multicenter controlled clinical trial designed to test whether the drug combination extended release niacin plus simvastatin is superior to simvastatin alone, at comparable levels of in-treatment LDLcholesterol (LDL-C), for ..
  16. Elucidation of Tissue-Specific Transcriptomic Profiles in Cardiometabolic Disease
    Muredach P Reilly; Fiscal Year: 2013
    ..In the Genetics of Evoked-Responses to Niacin and Endotoxemia (GENE) study, we recruited healthy individuals (N=286) to an inpatient protocol and collected ..
  17. Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial
    DANIEL JAMES RADER; Fiscal Year: 2013
    ..therapy (to raise HDL-C and lower both triglycerides and LDL-C) with simvastatin plus extended- release niacin (niacin) will reduce cardiovascular events more than LDL-lowering alone with simvastatin in patients with ..
  18. Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
    KEVIN DOUGLAS O'BRIEN; Fiscal Year: 2012
    ..changes in HDL that are associated with impairment of its normal function but that are improved with statin+niacin therapy...
  19. DOES ATHEROSCLEROSIS REGRESS WITH THERAPY FOR LOW HDLC?
    Bruce Brown; Fiscal Year: 2000
    ..o.) and women (less than 67 y.o.) to double-blinded therapy, assigned in a factorial design: 1) mid-dose niacin (500 mg qid), plus simvastatin (20 mg qd); 2) an antioxidant cocktail (vitamin C (500 mg bid), E (400 IU bid), and ..
  20. FUNCTIONAL CHARACTERISTICS OF THE LEFT HEART
    HAROLD DODGE; Fiscal Year: 1990
    ..natural history of coronary atherosclerotic lesions and the effect of serum lipid lowering with colestepol plus niacin or mevinolin and also cholestyramine on the rate of lesion progression...
  21. BIOSYNTHESIS OF VITAMIN B1 AND VITAMIN B6
    IAN SPENSER; Fiscal Year: 2000
    ..coli, since other Vitamins (e.g., thiamin, niacin) have distinct modes of origin in prokaryotes and eukaryotes...
  22. PROCESSING OF NUTRITIONAL ASPECTS OF BREAST MILK
    KHEM SHAHANI; Fiscal Year: 1980
    ..to the effects of slow freezing, quick freezing and freeze dehydration and storage upon certin B vitamins (niacin, biotin and pantothenic acid), enzymes such as protease, lysozyme, lipase and lactoperoxidase, and several lipid ..
  23. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2007
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  24. EVALUATING CORONARY LESION CHARGES USING NEURAL NETWORKS
    Stanley Azen; Fiscal Year: 1993
    CLAS, a randomized, controlled clinical trial testing niacin/colestipol plus diet therapy in non-smoking men with previous coronary bypass surgery, has demonstrated treatment benefits using both a) a coronary endpoint determination by a ..
  25. Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
    Mohammad Khan; Fiscal Year: 2007
    ..If successful, this approach potentially could be immediately extended for clinical applications. [unreadable] [unreadable] [unreadable]..
  26. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2006
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  27. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 2001
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  28. A TOPICAL MICRONUTRIENT DELIVERY SYSTEM
    Jaber Qasem; Fiscal Year: 2001
    ..A growing body of evidence demonstrates that micronutrients including vitamins B6, B12, C, E, folate, and niacin are involved in the maintenance of genomic integrity of skin cells via mechanisms ranging from scavenging ROS to ..
  29. Topical Micronutrient Delivery System
    Hyuntae Kim; Fiscal Year: 2005
    ..are to design, synthesize, characterize and evaluate the topical delivery properties of specific pronutrients (niacin, vitamin E, folate, Q1O, and lipoate) to evaluate the safety, tolerance, and efficacy, singly and in combinations ..
  30. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2002
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  31. A Transdermal Hypolipidemic Niacin Prodrug
    Hyuntae Kim; Fiscal Year: 2002
    b>Niacin has been used as first-line drug therapy for elevated serum cholesterol because of its broad efficacy on multiple lipid components as well as its low cost...
  32. LIPOPROTEIN(A)-CHOLESTEROL ASSAY BY LECTIN PRECIPITATION
    LEO SEMAN; Fiscal Year: 1993
    ..Elevated Lp(a) levels can be treated with niacin. Lp(a) differs from other lipoproteins by the presence of a glycoprotein called apolipoprotein(a) [apo(a)], which ..
  33. BIOCHEMICAL PHARMACOLOGY OF NIACIN
    Jason Morrow; Fiscal Year: 1990
    Nicotinic acid (niacin) is a B vitamin with potent hypolipidemic effects. Niacin administration has been related to a reduction in coronary heart disease mortality and overall mortality after recovery from myocardial infarction...
  34. ATHEROSCLEROSIS PROGRESSION/REGRESSION IN MAN
    DAVID BLANKENHORN; Fiscal Year: 1990
    The existing project is a controlled atherosclerosis regression trial using either niacin/colestipol or placebo in men who have had coronary artery bypass surgery...
  35. Does Raising HDL-C with Niacin Improve Endothelial Function in Early CKD?
    Vandana Menon; Fiscal Year: 2009
    ..b>Niacin is the most effective agent available to increase HDL-C levels and appears to improve endothelial function in non- ..
  36. EVALUATION OF TAURINE AND NIACIN IN LUNG FIBROSIS
    SHIRI GIRI; Fiscal Year: 1999
    ..The finding that dietary supplementation with taurine and niacin consistently, offers a marked protection against bleomycin (BL)-induced ILF in rodent models has opened a ..
  37. Tuning-Up Human Metabolism
    Bruce Ames; Fiscal Year: 2005
    ..g. homocysteine accumulation in MTHFR: riboflavin; alcohol intolerance in half of Asians: niacin. 2) Testing the effectiveness of other metabolites and micronutrients...
  38. Targeting cofactor biosynthesis in biodefense pathogens
    Andrei Osterman; Fiscal Year: 2009
    ..In addition to setting the stage for the development of new antibiotics, this study will impact our understanding of an important class of key biosynthetic enzymes in the vitamin/cofactor metabolism of bacterial pathogens. ..
  39. Effects of Chromium on Progression of Insulin Resistance
    Peter Havel; Fiscal Year: 2006
    ..The results of these studies will provide valuable information for the design and implementation of new clinical studies examining the effects of chromium supplements in the management of metabolic syndrome in humans. ..
  40. NON INVASIVE MRI OF HUMAN VULNERABLE PLAQUE
    Valentin Fuster; Fiscal Year: 2001
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  41. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  42. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....
  43. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2008
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  44. Mentored Career Development in Patient Oriented Research
    Daniel Rader; Fiscal Year: 2006
    ..abstract_text> ..
  45. Postprandial Lipemia and Endothelial Function In ACCORD
    Henry Ginsberg; Fiscal Year: 2004
    ....
  46. Gordon Research Conference: Lipoprotein Metabolism 2004
    Daniel Rader; Fiscal Year: 2004
    ....
  47. Estrogen and Mechanisms of Cardiomyocyte Protection
    Richard Karas; Fiscal Year: 2009
    ....
  48. Perfluorocarbon Materials As Drug Delivery Vehicles
    Hans Joachim Lehmler; Fiscal Year: 2004
    ..abstract_text> ..
  49. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  50. Mentored Clinical Research Scholar Program
    Henry Ginsberg; Fiscal Year: 2006
    ..They believe firmly that this K12 CRS Program will have an immense impact on the future of patient-oriented research in the next decades. [unreadable] [unreadable] [unreadable]..
  51. CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide greater understanding of the role of the local inflammatory response in atherosclerosis and its regulation by apoE. ..
  52. P20-Mediated Suppression of Vascular Force
    Christopher Rembold; Fiscal Year: 2004
    ..Many current treatments target smooth muscle to reduce tone. It is possible that targeting the force suppression pathway (i.e. p20) might provide comparable benefits. ..
  53. HDL metabolism: Influence of extracellular lipases
    Daniel Rader; Fiscal Year: 2009
    ....
  54. NUTRITION ACADEMIC AWARD
    Michael Miller; Fiscal Year: 2004
    ..Compliance with ATP II and JNC VI recommendations will also be assessed. In addition, medical students' diets and blood lipid levels will be assessed and tracked. ..
  55. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2008
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  56. MOLECULAR & CLINICAL EVALUATION OF LOW HDL SYNDROMES
    Michael Miller; Fiscal Year: 2003
    ..Further understanding of the molecular basis of isolated low HDL-C and its potential clinical sequelae (e.g., CAD), may therefore aid in the development of therapeutic strategies to effectively treat this disorder. ..
  57. NO-CGMP INHIBITION OF UROGENITAL SMOOTH MUSCLE
    Christopher Rembold; Fiscal Year: 2004
    ....
  58. Distribution of PCB Atropisomers
    Hans Joachim Lehmler; Fiscal Year: 2008
    ..The long term career goal is to establish Dr. Lehmler as an investigator with independent research status and funding. ..
  59. CAROTID PLAQUE COMPOSITION BY MRI DURING LIPID-LOWERING
    Xue Qiao Zhao; Fiscal Year: 2010
    ..The HDL target for the two niacin-treated groups is to increase 10 mg/dl from baseline...
  60. HIGH DENSITY LIPOPROTEIN SUBSPECIES AND CORONARY DISEASE
    Bela Asztalos; Fiscal Year: 2003
    ..The investigators state that these studies should provide better understanding about the diagnosis and treatment of HDL deficiency for the prevention of CHD. ..
  61. MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
    ERNST SCHAEFER; Fiscal Year: 2009
    ..The results of this work will provide important insight into the contribution of allelic variation in the pathways of HDL metabolism, inflammation, and insulin resistance to the complex phenotype of low HDL-C. ..